Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocytemacrophage colony stimulating factor in patients with stage III and IV melanoma.

MLA

Sussman, Tamara A., et al. “Phase II Trial of Vaccination with Autologous, Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocytemacrophage Colony Stimulating Factor in Patients with Stage III and IV Melanoma.” Frontiers in Oncology, May 2024, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fonc.2024.1395978.

APA

Sussman, T. A., Severgnini, M., Giobbie-Hurder, A., Friedlander, P., Swanson, S. J., Jaklitsch, M., Clancy, T., Goguen, L. A., Lautz, D., Swanson, R., Daley, H., Ritz, J., Dranoff, G., & Hodi, F. S. (2024). Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocytemacrophage colony stimulating factor in patients with stage III and IV melanoma. Frontiers in Oncology, 1–11. https://doi.org/10.3389/fonc.2024.1395978

Chicago

Sussman, Tamara A., Mariano Severgnini, Anita Giobbie-Hurder, Philip Friedlander, Scott J. Swanson, Michael Jaklitsch, Thomas Clancy, et al. 2024. “Phase II Trial of Vaccination with Autologous, Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocytemacrophage Colony Stimulating Factor in Patients with Stage III and IV Melanoma.” Frontiers in Oncology, May, 1–11. doi:10.3389/fonc.2024.1395978.